New hope for breast cancer patients who stopped responding to standard hormone therapy
NCT ID NCT07354022
Summary
This study compares two different drug combinations for people with advanced breast cancer that has stopped responding to previous hormone treatments. Researchers will test whether HRS-8080 plus dalpiciclib works better than the current standard treatment (fulvestrant plus dalpiciclib) at controlling cancer growth. The trial involves 912 participants and focuses on how long the treatment keeps the cancer from worsening and what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital Fifth Medical Center
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact
Conditions
Explore the condition pages connected to this study.